A Glycerophospholipid Metabolism-Based Prognostic Model Guides Osteosarcoma Therapy
Translational Oncology · 2026-01 · 63 · 102572
DOI: 10.1016/j.tranon.2025.102572 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Oncology, 2026-01. Verfasst von Yong Wen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, the second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Second Affiliated Hospital of Guangzhou University of Chinese Medicine.
Abstract (Originalsprache)
BACKGROUND: Glycerophospholipid metabolism regulates membrane synthesis, signaling, and cell homeostasis, but its role in osteosarcoma (OS) progression, immunity, and therapy remains unclear. METHODS: We integrated bulk transcriptome data from TARGET (n = 85) and GEO cohorts (n = 124) with single-cell RNA-seq data (GSE162454, six OS samples). Glycerophospholipid metabolism activity was quantified using five algorithms to generate a GAS score. Prognostic genes were identified via univariate Cox regression, followed by Lasso-Cox modeling. Downstream analyses included cell communication, immune infiltration, mutation profiling, drug sensitivity, and immunotherapy response. RESULTS: Twelve cell types were identified; malignant OS cells showed the lowest glycerophospholipid metabolism. Nine genes correlated with GAS (r=±0.2, p 0.7). High GAS patients exhibited elevated immune gene expression and copy number alterations (p < 0.05). GAS remained an independent prognostic factor (HR=3.58, 95 %CI:2.23-5.74, p < 0.001). Drug prediction highlighted lovastatin, simvastatin, and tamatinib for high-risk patients, and higher GAS associated with poor immunotherapy response (p < 0.01). CONCLUSION: GAS-based stratification not only robustly predicts OS prognosis but also reveals interactions between glycerophospholipid metabolism and tumor immunity, guiding personalized therapeutic strategies and highlighting novel drug candidates for high-risk patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopedics, the second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, China.
- Department of Laboratory Medicine, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China.
- Department of Orthopedic Oncology, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
- The second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, China.
- Department of Laboratory Medicine, Taizhou Municipal Hospital (Taizhou University Affiliated Municipal Hospital), School of Medicine, Taizhou University, Taizhou 318000, Zhejiang, China. Electronic address: zhangjin_jhb…
- Department of Orthopedics, the second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, China. Electronic address: Chenbolai337@163.com.
Förderung
- The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Zitieren
APA
Wen, Y., Wang, D., Wang, H., Zhao, J., Yao, L., Zhang, J., & Chen, B. (2026). A Glycerophospholipid Metabolism-Based Prognostic Model Guides Osteosarcoma Therapy. Translational Oncology, 63, 102572. https://doi.org/10.1016/j.tranon.2025.102572
Vancouver
Wen Y, Wang D, Wang H, Zhao J, Yao L, Zhang J, et al. A Glycerophospholipid Metabolism-Based Prognostic Model Guides Osteosarcoma Therapy. Translational Oncology. 2026;63:102572. doi:10.1016/j.tranon.2025.102572
BibTeX
@article{Wen2026,
author = {Wen, Yong and Wang, Donglian and Wang, Hongshen and Zhao, Jian and Yao, Li and Zhang, Jin and Chen, Bolai},
title = {A Glycerophospholipid Metabolism-Based Prognostic Model Guides Osteosarcoma Therapy},
journal = {Translational Oncology},
year = {2026},
volume = {63},
pages = {102572},
doi = {10.1016/j.tranon.2025.102572}
}
EUVIMED